Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19550989 | 1.00 | POLB (0.35) | POLBSLC6A2SLC6A4NAMPTABL1 | |
| SCHEMBL19551033 | 1.00 | POLB (0.35) | POLBSLC6A2SLC6A4NAMPTABL1 | |
| SCHEMBL18101277 | 0.98 | POLB (0.34) | POLBSLC6A2SLC6A4NAMPT | |
| Hydrochloric Acid SCHEMBL19551066 | 0.98 | POLB (0.34) | POLBSLC6A2SLC6A4NAMPT | |
| Hydrochloric Acid SCHEMBL19551065 | 0.98 | POLB (0.34) | POLBSLC6A2SLC6A4NAMPT | |
| SCHEMBL18101257 | 0.98 | POLB (0.34) | POLBSLC6A2SLC6A4NAMPT | |
| SCHEMBL18101224 | 0.98 | POLB (0.34) | POLBSLC6A2SLC6A4NAMPT | |
| SCHEMBL18122009 | 0.98 | POLB (0.34) | POLBSLC6A2SLC6A4NAMPT | |
| SCHEMBL18101223 | 0.98 | POLB (0.34) | POLBSLC6A2SLC6A4NAMPT | |
| SCHEMBL9815476 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452466-B1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10150760-B2 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| CN-101133072-B | Hydrogels for controlled release of bioactive materials | FIRMENICH & CIE | 2012-05-30 | — | — | CN | disclosed |
| CN-101133072-A | Hydrogels for controlled release of bioactive materials | FIRMENICH & CIE (CH) | 2008-02-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, GPR27 | POLB 3795/4885SLC6A2 1904/4885SLC6A4 2239/4885 |
| US-10150760-B2 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | TBXA2R, APLNR, GPR27 | POLB 3795/4885SLC6A2 1904/4885SLC6A4 2239/4885 |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, AGTR1 | POLB 4457/4885SLC6A2 2975/4885SLC6A4 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.